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Isolation of Sabin-Like Polioviruses from Wastewater in a
Country Using 
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Abstract
From 2001 to 2004, Switzerland switched from routine vaccination with oral polio vaccine (OPV) to
inactivated polio vaccine (IPV), using both vaccines in the intervening period. Since IPV is less
effective at inducing mucosal immunity than OPV, this change might allow imported poliovirus to
circulate undetected more easily in an increasingly IPV-immunized population. Environmental
monitoring is a recognized tool for identifying polioviruses in a community. To look for evidence of
poliovirus circulation following cessation of OPV use, two sewage treatment plants located in the
Zurich area were sampled from 2004 to 2006. Following virus isolation using either RD or L20B cells,
enteroviruses and polioviruses were identified by reverse transcription-PCR. A total of 20 out of 174
wastewater samples were positive for 62 Sabin-like isolates. One isolate from each poliovirus-positive
sample was analyzed in more detail. Sequencing the complete viral protein 1 (VP1) capsid coding
region, as well as intratypic differentiation (ITD), identified 3 Sabin type 1, 13 Sabin type 2, and 4 Sabin
type 3 strains. One serotype 1 strain showed a discordant result in the ITD. Three-quarters of the strains
showed mutations within the 5' untranslated region and VP1, known to be associated with reversion to
virulence. Moreover, three strains showed heterotypic recombination (S2/S1 and S3/S2/S3). The low
number of synonymous mutations and the partial temperature sensitivity are not consistent with
extended circulation of these Sabin virus strains. Nevertheless, the continuous introduction of
polioviruses into the community emphasizes the necessity for uninterrupted child vaccination to
maintain high herd immunity.
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From 2001 to 2004, Switzerland switched from routine vaccination with oral polio vaccine (OPV) to
inactivated polio vaccine (IPV), using both vaccines in the intervening period. Since IPV is less effective at
inducing mucosal immunity than OPV, this change might allow imported poliovirus to circulate undetected
more easily in an increasingly IPV-immunized population. Environmental monitoring is a recognized tool for
identifying polioviruses in a community. To look for evidence of poliovirus circulation following cessation of
OPV use, two sewage treatment plants located in the Zurich area were sampled from 2004 to 2006. Following
virus isolation using either RD or L20B cells, enteroviruses and polioviruses were identified by reverse
transcription-PCR. A total of 20 out of 174 wastewater samples were positive for 62 Sabin-like isolates. One
isolate from each poliovirus-positive sample was analyzed in more detail. Sequencing the complete viral protein
1 (VP1) capsid coding region, as well as intratypic differentiation (ITD), identified 3 Sabin type 1, 13 Sabin type
2, and 4 Sabin type 3 strains. One serotype 1 strain showed a discordant result in the ITD. Three-quarters of
the strains showed mutations within the 5 untranslated region and VP1, known to be associated with reversion
to virulence. Moreover, three strains showed heterotypic recombination (S2/S1 and S3/S2/S3). The low number
of synonymous mutations and the partial temperature sensitivity are not consistent with extended circulation
of these Sabin virus strains. Nevertheless, the continuous introduction of polioviruses into the community
emphasizes the necessity for uninterrupted child vaccination to maintain high herd immunity.
The global polio eradication initiative was launched in 1988.
Substantive progress has been made toward this goal, but further
work is still required (11, 12, 21, 29). Successful eradication of the
cause of an infectious disease, exemplified by that of Variola virus,
has at least four fundamental requirements: (i) absence of an
animal reservoir; (ii) effective vaccines and, in the case of live-
attenuated viruses, genetically stable vaccines; (iii) absence of
long-term virus carriers; and (iv) sensitive tools to detect the
presence of the causal agent. In the case of poliovirus eradication,
these requirements have not been completely met. The basic
strategy of the polio eradication initiative involves achieving high
levels of routine immunization, mass vaccination, supplementary
mop-up immunization activity, and poliovirus surveillance based
on virological investigation of acute flaccid paralysis (AFP) cases
(51, 56). There are two effective vaccines: inactivated polio vac-
cine (IPV), originally developed by Jonas Salk and colleagues,
and the live-attenuated oral polio vaccine (OPV) of Albert Sabin
(39). Both vaccines provide effective protection from poliomyeli-
tis. However, IPV induces less mucosal immunity in the gut than
OPV, a prerequisite for reducing intestinal reinfection, virus
shedding, and transmission to susceptible contacts (33, 37, 41, 44,
45). OPV, which better protects from infection, suffers from other
inadequacies that complicate the ongoing initiative (11, 12, 21,
29). One inadequacy is the emergence of virulent vaccine-derived
polioviruses (VDPVs) upon long-term replication in immunod-
eficient persons (iVDPV) or following sustained circulation in
populations with immunity gaps (cVDPV). Ambiguous VDPVs,
such as environmental isolates, represent a category of virulent
polioviruses that cannot easily be assigned to iVDPV or cVDPV
(29). Additional challenges for the initiative are poorly under-
stood deficiencies in vaccine efficacy (24) and the low clinical
attack rate following infection with virulent polioviruses (1:100
paralytic case/infections). This calls for specific and sensitive vi-
rus-tracking tools. AFP surveillance is presently the gold standard
for meeting those requirements (56).
The three serotypes of poliovirus are members of the family
Picornaviridae (20, 40, 55, 61). The viruses possess a single-
stranded RNA genome of approximately 7,400 nucleotides (nt).
Upon infection, the genomic RNA is translated as a polyprotein,
which is then processed by proteases into functional proteins. The
structural proteins are located within the N-terminal P1 region
and the nonstructural proteins within the succeeding P2 and P3
regions of the polyprotein. Similar to some other RNA viruses,
the virus-encoded RNA-dependent RNA polymerase is error
prone and lacks proofreading activity. This results in a high mu-
tation frequency for these viruses. The molecular evolution of
polioviruses is characterized by selective propagation of virus vari-
ants that are generated through mutations and heterotypic or
intragenus recombination (29). During wild-type (wt) poliovirus
infection, a steady accumulation of mostly synonymous mutations
is the major contribution to genetic evolution (23). In addition, an
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early burst of nonsynonymous mutations and recombination is
characteristic of the evolution of the Sabin strains in the guts of
vaccinees and their susceptible contacts. This helps the virus to
regain replicative fitness (64) and to revert to the virulent pheno-
type with an increased possibility of causing neurologic disease.
There are a number of serotype-specific nucleotide positions as-
sociated with attenuation (29). Therefore, observation of the re-
version of these attenuating mutations at these positions implies
an increase in virulence. Nonetheless, other factors not solely
associated with these single-nucleotide changes could also play a
role in virulence (28). The number of synonymous mutations
within the region coding for the capsid protein viral protein 1
(VP1) is used to estimate the “age” of poliovirus strains, i.e., the
duration of in vivo replication in single or successive hosts (4, 14,
15, 23, 26). VDPVs are defined as viruses with a 1 to 15% nucle-
otide sequence difference within the VP1 region compared to the
parental Sabin vaccine strain of the same type (11, 29). Viral
isolates that display 1% nucleotide sequence difference from
the parental vaccine strain are defined as vaccine- or Sabin-like
(SL). In principal, both VDPVs and SL viruses can cause polio-
myelitis, but at different rates on average. In settings with low
vaccination coverage, however, the VDPVs are of growing con-
cern in the efforts toward global polio eradication (12).
There are a few European countries that have relied exclusively
and successfully upon IPV to control both poliomyelitis and the
circulation of wt polioviruses. This success has been achieved by
maintaining high vaccination coverage (17, 41). Similar to other
countries, Switzerland before 2001 used mainly OPV. Between
2001 and 2004, Switzerland used a combination of IPV and OPV
for safety reasons, i.e., to prevent cases of vaccine-associated par-
alytic poliomyelitis. In 2004, there was a switch to the IPV-only
vaccination schedule. The reported vaccination coverage of chil-
dren less than 2 years old with three doses of IPV is 94% (9).
Following the switch from OPV to IPV, the Swiss population now
consists of an older age group that was immunized with OPV and
a growing younger age group that is immunized only with IPV.
The national AFP surveillance system is important but not opti-
mal, because a low number of stool samples are submitted for
virological examination (59).
Since IPV provides only limited protection against intestinal
infection, a possible risk is the undetected circulation of im-
ported wt or vaccine poliovirus in persons with only IPV-
induced immunity. Furthermore, vaccine viruses silently circu-
lating among individuals lacking mucosal immunity could be a
potential source for generation of cVDPV. Consistent with
reports of the international spread of poliovirus, such strains
could provoke a poliomyelitis outbreak in a setting with inad-
equate immunity. This prompted the initiation of a study to
investigate the prevalence of poliovirus in municipal wastewa-
ter samples in Switzerland following the cessation of routine
OPV use. In this study, we characterized poliovirus-positive
sewage samples collected between January 2004 and October
2006 by employing a new protocol for virus concentration and
either RD or L20B cells for primary virus isolation.
MATERIALS AND METHODS
Wastewater samples. A total of 174 wastewater samples were collected be-
tween January 2004 and October 2006 from two sewage treatment plants in
Werdhoelzli (Wh) and Kloten-Opfikon (KO). The Wh plant serves Zurich, the
largest city in Switzerland, with approximately 340,000 inhabitants. The KO plant
serves a community of approximately 55,000 persons near the Zurich interna-
tional airport. The grab samples for virus isolation were usually taken once a
week, transported to the laboratory within 1 to 2 h, and processed immediately
according to the WHO guidelines (57).
Sample preparation. The sample-processing protocol has been described in
detail elsewhere (3, 34, 53). Briefly, AlCl3 (final concentration, 0.5 mM) was
added to 500 ml of sewage sample, and the pH was adjusted to 3.5. Following the
addition of 250 l of an SiO2 slurry (5), the samples were stirred for 30 min,
followed by centrifugation at room temperature and 1,500 g for 5 min to pellet
the SiO2. The virus was recovered by rocking the pellet for 20 min with 3 ml of
50 mM glycine (pH 9.5) containing 3% (wt/vol) beef extract (B-4888; Sigma
Chemie GmbH, Buchs, Switzerland). After centrifugation for 5 min at 4°C and
1,500  g, the supernatants were adjusted to pH 7.5 and treated three times with
3 ml chloroform with rocking for 10 min each. After a final centrifugation, the
concentrates were used to inoculate cell cultures.
Virus isolation. RD and/or L20B cells (60) were used throughout the exper-
iments. Both cell lines were cultivated in minimal essential medium supple-
mented with 7.5% fetal calf serum. Two different cell culture procedures were
used during the course of the studies, differing in the cell lines initially inoculated
and the nature of subsequent passages (Fig. 1). Environmental concentrates (3
ml) were adjusted to 19 ml with cell culture medium, and cell monolayers in two
96-well plates were inoculated with 0.1 ml per well of this suspension. On each
plate, one well was mock infected as a negative control. The plates were incu-
bated for 6 to 8 days at 36°C. Blind and second passages were typically performed
in 24-well plates. With a focus on the biohazard and to avoid possible cross-
contamination during laboratory work, a standard operating procedure was
strictly followed throughout.
Determination of virus recovery efficiency. The in-house SiO2 protocol was
compared in parallel with the two-phase separation protocol (dextran 40 and
polyethylene glycol 6000) recommended by WHO (57). A total of seven exper-
iments with spiked wastewater were performed. One experiment was defined as
spiking two 500-ml samples with 10,000 50% cell culture infective doses
(CCID50) of the Mahoney strain, and the virus recovery efficiency was deter-
mined based on the measured infectivity by titration on L20B cells using a series
of log5 dilutions and six inoculated cultures for each viral dilution.
Molecular characterization of viruses. RNA was purified, using a Qiamp Viral
RNA Mini Kit (Qiagen GmbH, Basel, Switzerland), from the supernatants of
wells that showed cytopathic effect. Reverse transcription (RT) and PCR were
done with a one-tube, two-step protocol (20 l for RT and 50 l for PCR; both
from Promega AG, Du¨bendorf, Switzerland). RT was performed with specific
antisense primers. All primers used (Table 1) were purchased from Microsynth
GmbH, Balgach, Switzerland. Following agarose gel electrophoresis, the PCR
products were purified (Qiaex II; Qiagen GmbH) and subjected to sequencing
(Microsynth GmbH). Sequences were routinely obtained from both strands, and
multiple-sequence alignments were carried out with the program CLUSTALW
(http://www.ebi.ac.uk/clustalw).
Two generic primer pairs targeting the 5 untranslated region (5 UTR)
(HuEV2.re and HuEV2.fw) (1) and the VP1 region (All-EV.re and All-EV.fw)
(43) were used to detect enterovirus RNA. Three primer pairs were used as
the basis for poliovirus characterization. The first pair (Y7 and Q8) amplified the
entire VP1 coding region to allow complete sequencing of the region (54). The
second pair (APAN and UG15) targeted the P3 coding region of the nonstruc-
tural proteins (6, 25). The third pair (HuEV2.re and UG52) allowed amplifica-
tion and sequencing of the partial poliovirus 5 UTR. Reactivity with Y7 and Q8
indicated the presence of a poliovirus RNA, and sequencing of the resulting
amplicons identified both the serotype (1, 2, or 3) and some virulence attributes,
namely, SL versus VDPV versus wt poliovirus. The primers used in this study are
summarized in Table 1. VP1 sequences were compared with the respective Sabin
prototype strains (GenBank accession no. AY082688.1, AY082679.1, and
AY082683.1). The numbers of synonymous and nonsynonymous nucleotide sub-
stitutions were determined with the program DIVERGE (GCG package, version
10.3; Genetics Computer Group, Madison, WI). Based on this, the “ages” of the
isolates were calculated (15, 64). Sequencing of the amplicons from the 5 UTR
gave additional information regarding reversion of attenuation. Within the 5
UTR the most important determinant of attenuation for Sabin type 1 is the
nucleotide “G” at position 480; for Sabin type 2, it is “A” at position 481, and for
Sabin type 3, it is “U” at position 472. PCR amplicons of the P3 genomic region
were subjected to restriction fragment length polymorphism analysis (SpeI) to
screen for recombinants (6). Strains with altered SpeI patterns were sequenced
and characterized based on multiple sequence alignment with published se-
quences (GenBank accession no. V01150, X00595, and X00925).
Replication capacity at supraoptimal temperature. In contrast to wt poliovi-
rus, SL viruses do not grow well at the elevated temperature of 40°C. The
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infectivities of isolates were measured in parallel by titration at 36°C and 40°C on
L20B cells (7, 42). Following inoculation, the 96-well plates were sealed in plastic
bags and submerged in a water bath at the specified temperature. The results
were recorded 3 days postinoculation. A titer reduction of 2 log10 units at
elevated temperature was observed with the reference strain Mahoney of polio-
virus type 1. Therefore, a difference of 2 log10 units was considered to reflect
temperature sensitivity.
Intratypic differentiation (ITD). The strains were characterized by an antigen-
based enzyme-linked immunosorbent assay (ELISA) using type-specific cross-
absorbed anti-poliovirus sera and by a molecular test, using Sabin-specific primers,
according to WHO guidelines (60).
Nucleotide sequence accession numbers. The VP1 sequences determined dur-
ing this study have been deposited in GenBank (accession no. DQ841124 to
DQ841140 and EF490669 to EF490681).
RESULTS
Efficiency of virus recovery. The in-house SiO2 protocol and
the two-phase separation protocol were compared in parallel
using spiked sewage samples. Virus recovery using our SiO2
protocol (60 30%) was significantly higher (P 0.05; U test)
than with the two-phase separation protocol (30  25%) rec-
ommended by WHO. The observed variability of both proto-
cols between samples was likely due to varied properties of the
sewage samples and was not investigated further. All further
studies were based on the in-house SiO2 protocol.
Environmental poliovirus isolations. A total of 20 out of 174
(11.5%) wastewater samples were positive for any poliovirus iso-
lation and resulted in recovery of 62 poliovirus strains, namely, 46
from 2004 to 2005 and 16 in 2006 (Table 2). The former 46 strains
were recovered upon primary isolation on RD cells from 13 out of
88 samples. The latter 16 strains were found in 7 out of 86 samples
by primary isolation on L20B cells. Sequencing of the VP1 region
invariably identified these strains as SL (see below). During 2004
and 2005, there were 410 and 1,250 virus isolations, respectively,
indicated by growth in a well on RD cell plates. Of these, 10 and
39 could be further propagated on L20B cells (Fig. 1 and Table 2).
Two of the three nonpolioviruses from 2005 that grew on L20B
cells were identified as human enteroviruses based on amplifica-
tion with the enterovirus generic primers HuEV2.re and
HuEV2.fw, leaving one strain with undetermined identity.
FIG. 1. Flowchart of poliovirus isolation protocols. For primary virus isolation, either RD or L20B cells were used. The second passage was on
L20B cells. ve, cytopathic effect within 6 to 8 days; ve, no cytopathic effect within 6 to 8 days.
TABLE 1. Primers used in this study for amplification and sequencing
Primer Sequence (5–3) Polarity Positiona Productsize (kb) Target sequence
b Reference
HuEV2.re ACCGGATGGCCAATCCAA Antisense 638–621
HuEV2.fw CCTCCGGCCCCTGAATG Sense 444–460 0.2 EV/5 UTR 1
UG52 CAAGCACTTCTGTTTCCCCGG Sense 162–182 0.48 PV/5 UTR 25
Q8 AAGAGGTCTCTATTCCACAT Antisense 3504–3485
Y7 GGITTTGTGTCAGCITGCAATGA Sense 2399–2421 1.11 PV/VP1 54
ALL-EV.re CICCIGGIGGIAYRWACAT Antisense 2969–2951
ALL-EV.fw MIGCIGYIGARACNGG Sense 2613–2628 0.36 EV/VP1 43
APAN TTTTTTTTTTTTTTTTTTCTCCG Antisense 7436 6
UG15 CTGTCACCAACCAGCAAACTT Sense 4936–4956 2.53 PV/P3 region 25
a Positions are relative to the genome of Sabin 1 (GenBank accession no. V01150).
b EV, enterovirus; PV, poliovirus; P3, viral nonstructural protein region.
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The modified protocol implemented during 2006 using L20B
cells for primary isolation (Fig. 1) resulted in 58 cytopathic-
effect-positive cultures (Table 2). Of these, 16 (27.6%) were
subsequently identified as polioviruses. Surprisingly, none of
the remaining 42 strains reacted with the enterovirus generic
primers HuEV2.re and HuEV2.fw. A second primer pair with
panenterovirus specificity (All-EV.re and All-EV.fw), which
targets the VP1 genomic region (43), was then used success-
fully to amplify the RNAs of 10 of these 42 nonpolioviruses,
leaving 32 strains with undetermined identities. Amplicons
from 6 of the 10 nonpoliovirus enteroviruses were sequenced,
and a BLAST search showed that the most closely related
sequences were from bovine enteroviruses (data not shown).
In conclusion, the modified protocol detected, in addition to
polioviruses, both presumptive bovine enteroviruses and a sub-
stantial number of viruses with undetermined identities. This
finding with L20B cells thus contrasted with the results that
were obtained when RD cells were used for primary isolation.
Two of the 20 poliovirus isolations (Wh/77P and Wh/4P)
could be achieved in cell culture only after one blind passage
(samples 2 and 13, in RD and L20B, respectively). In the
remaining samples, the numbers of strains isolated during the
first passage ranged from 1 (in 10 samples) to 16 in sample no.
6 (Table 3). Only four of the poliovirus-positive samples had
more than two strains isolated. Considering the efficiency of
virus recovery with the SiO2 protocol (60%), the original titer
was estimated to be 30 CCID50/500 ml. Based on the nucle-
otide sequence of the VP1 region, the strains recovered from
a given sample were basically identical (1-nt difference), i.e.,
there was no evidence of heterotypic virus isolations.
Molecular characterization of isolated polioviruses. A total
of 20 strains, 1 strain from each poliovirus-positive sample,
were characterized in more detail (Tables 3 and 4). The num-
bers of synonymous mutations within the VP1 region were 1,
3, and 5 in 17, 2, and 1 strains, respectively. This indicated that
the strains were either “newborn” (no synonymous substitu-
tion) or “young” (1 to 10 synonymous substitutions), i.e., the
ages of these strains were invariably less than 1 year (64). In
particular, the calculated ages of these strains were 6 weeks
for 17 strains and 3.7 2.2 months (Wh/596), 4.1 2.2 months
(KO/42.3), and 6.5  3.0 months (Wh/4P) for the remaining
strains. Most strains had reversed the attenuating mutations
(29) in both the VP1 region and the 5 UTR. Three strains
TABLE 2. Isolation of (polio)viruses from two sewage
treatment plantsa
Yr
No. of
samples with
poliovirus/no.
of samples
tested (%)
No. of
cytopathic
strains in
P1 (RD)
No. of poliovirus strains/total
no. of strains (%) in:
P2 (L20B) P1,2 (L20B)
2004 3/30 (10) 410 10/10 (100) ND
2005 10/58 (17.2) 1,250 36/39 (92.3) ND
2006 7/86 (8.1) NDb ND 16/58 (27.6)
Total 20/174 (11.5) 1,660 46/49 (93.9) 16/58 (27.6)
a Using either RD or L20B cells for primary isolation (P1) and L20B cells for
a second passage (P2). Sewage sample concentrates were used to inoculate cells
grown in two microtitration plates.
b ND, not determined.
TABLE 3. Origins and overview of genotypic and phenotypic characteristics of environmentally derived polioviruses
Sample
no. Yr/wk
No. of
strains
isolateda
Origin/strain
studied Genotype
b
No. of
synonymous/all
mutations in
VP1c
Nucleotide at
positiond Recombinant
e RCTf
ITDg
ELISA PCR
1 2004/19 2 KO/50 Sabin 1 1/1 480G 6.0 SL SL
2 2005/25 1 Wh/77P Sabin 1 1/6 480A 4.0 NSL SL
3 2006/14 1 Wh/14.13 Sabin 1 0/4 480A 5.5 SL SL
4 2004/16 6 Wh/167 Sabin 2 1/2 481G 4.0 SL SL
5 2005/26 1 Wh/80 Sabin 2 0/0 481A 4.75 SL SL
6 2005/36 16 Wh/596 Sabin 2 3/4 481G 4.5 SL SL
7 2005/39 2 Wh/679 Sabin 2 0/2 481G 4.5 SL SL
8 2005/40 1 Wh/777 Sabin 2 0/1 481G 5.5 SL SL
9 2005/41 11 Wh/786 Sabin 2 0/1 481G 4.5 SL SL
10 2005/43 1 Wh/870 Sabin 2 0/2 481G 4.75 SL SL
11 2005/47 1 Wh/939 Sabin 2 1/4 481A 5.75 SL SL
12 2005/50 1 Wh/998 Sabin 2 0/1 481G S2/S1 5.0 SL SL
13 2006/04 1 Wh/4P Sabin 2 5/9 481G SpeI 4.0 SL SL
14 2006/30 1 KO/30.1 Sabin 2 0/0 481A 5.5 SL SL
15 2006/31 9 Wh/31.32 Sabin 2 0/2 481G 4.25 SL SL
16 2006/42 1 KO/42.3 Sabin 2 3/5 481G 5.0 SL SL
17 2004/09 2 Wh/70 Sabin 3 0/0 472C 3.5 SL SL
18 2005/36 1 KO/565 Sabin 3 0/0 472U 5.25 SL SL
19 2006/02 2 Wh/2.1 Sabin 3 0/1 472C S3/S2/S3 3.75 SL SL
20 2006/03 1 Wh/3.5 Sabin 3 0/1 472C S3/S2/S3 4.25 SL SL
a Number of cultures (out of 190) with poliovirus growth (see Materials and Methods). Multiple strains recovered from a given sample were essentially identical as
deduced from the nucleotide sequence of the VP1 capsid region (data not shown).
b According to the nucleotide sequence of the VP1 gene.
c Compared with the respective Sabin sequence.
d Letters in boldface indicate Sabin-type nucleotides.
e Sabin-type sequences determined following restriction enzyme (SpeI) fingerprinting. SpeI, mutational loss of cleavage site.
f RCT, reproductive capacity at supraoptimal temperature: log10 (CCID50 at 36°C/CCID50 at 40°C). In this assay, PV1 (Mahoney) showed a 2.0 log10 reduction in
titer.
g ITD according to WHO guidelines (60). NSL, non-SL.
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were heterotypic recombinants within the nonstructural coding
region. Strain Wh/998 (Sabin 2; zero synonymous changes in
VP1) recombined between nt 6248 and nt 6282, revealing an
S2/S1 genotype. The same site of recombination was previously
observed in an immunocompromised poliomyelitis patient
(15). Strains Wh/2.1 and Wh/3.5 (Sabin 3; both zero synony-
mous changes in VP1) recombined between nt 6988 and nt
7001 from S2 to S3. Since both strains are S3 in the VP1 region,
as revealed by sequence determination, these two strains have
an S3/S2/S3 genotype. The S3/S2/S3 genotype has also previ-
ously been observed in stool samples from healthy vaccinated
children (19). An additional strain (Wh/4P) had lost one of the
two type 2-specific SpeI cleavage sites within the same region.
All 20 strains remained, at least partially, temperature sensitive
(Table 3). Upon ITD, a single strain (Wh/77P) was recorded
with a discordant result by ELISA, indicating some antigenic
change and the need for further characterization. This anti-
genic result was consistent with the finding of five nonsynony-
mous substitutions within the VP1 region.
The 20 SL strains had accumulated zero to nine substitutions
within the VP1 region, giving rise to a total of 46 mutations
(Table 4). Fifteen of these were synonymous, and 31 were
nonsynonymous. In contrast to the findings of Yakovenko et al.
(64), only a minority of the observed amino acid changes (9/31)
were located within the antigenic region of VP1. These
changes in antigenic-site amino acids were also seen in only
four positive samples and five of nine observed from a single
isolate (Wh/77P). In addition, there was an indication of a
discordant nucleotide consensus at position 2493 (boldface)
among the type 3 SL viruses, namely, “ACU” in Wh/70 and
KO/565 and “AUU” in Wh/2.1 and Wh/3.5. Consequently, the
deduced amino acids were either threonine or isoleucine, re-
spectively. This discordance may reflect the presence of corre-
sponding type 3 viral genotypes in diverse vaccine seeds (47).
This study revealed a number of amino acid changes that were
not previously recorded in derivates of OPV (Table 4). The
possible significance of these changes cannot be judged due to
limitations in the number of observations in this study. This
may be addressed in future work.
DISCUSSION
Environmental poliovirus monitoring conducted over a
3-year period resulted in the detection of poliovirus in 20
samples from two locations in the Zurich area (Switzerland).
All of the 20 SL strains showed partial temperature sensitivity,
indicating some attenuated characteristics of the vaccine
strains. This is exemplified by a recent report (10) showing that
a type 2 SL isolate from an immunodeficient patient expressed
temperature sensitivity. Four of the 20 SL strains showed no
difference from the parental Sabin strains based on a compar-
ison of mutational markers within the VP1 region and the 5
UTR (Table 3). However, the remaining 16 strains displayed
substitutions at attenuation sites within the 5 UTR and the
VP1 region, and three of these strains were also heterotypic
recombinants (Table 3). Most of the 16 strains had accumu-
lated additional nonsynonymous substitutions within VP1 (Ta-
ble 4). Some of these mutations are known to contribute to the
gain of viral fitness and to occur in vaccinees in the early phase
of intestinal replication (13, 14, 23, 30, 31, 38, 64). It has been
reported that OPV strains can accumulate mutations during in
vitro propagation similar to those seen during in vivo replica-
tion (16, 48, 52). Even though the number of in vitro passages
was restricted to two, we cannot rule out the possibility that
TABLE 4. Nucleotide and amino acid changes observed within the
VP1 gene of environmentally derived polioviruses
Strain (Sabin
type)
Nucleotide substitution
at positiona
Change to
amino
acida
Contained in
antigenic
regionb
KO/50 (S1) G3313A
Wh/77P (S1) G2741A A088T 
A2749G I090M 
A2775C K099T 
A2795G T106A 
G3058A
C3171U A231Vc 
Wh/14.13 (S1) G2502A S008Nc 
G2776U K099N 
A2795U T106S 
A3059U I194F 
Wh/167 (S2) A2908G I143V 
A3342G
Wh/80 (S2)
Wh/596 (S2) G2715A
U2909C I143T 
G3258A
C3318U
Wh/679 (S2) U2909C I143T 
C2962U P161Sc,d 
Wh/777 (S2) U2909C I143T 
Wh/786 (S2) U2909C I143T 
Wh/870 (S2) A2527G N016Dc 
U2909C I143T 
Wh/939 (S2) A2785G S102Gc,d 
U2909A I143N 
A2986G K169Ec 
A3297G
Wh/998 (S2) U2909C I143T 
Wh/4P (S2) A2513U
C2568U E011Vc,d 
A2610G
G2742A
U2909C I143T 
A2950U I157Lc,d 
C3146U S222L 
A3255G
G3267A
KO/30.1 (S2)
Wh/31.32 (S2) A2527G N016Dc 
U2909C I143T 
KO/42.3 (S2) U2565C
G2631A
G2772A
U2909C I143T 
A2986G K169Ec 
Wh/70 (S3)e
KO/565 (S3)e
Wh/2.1 (S3)e G2636A A054T 
Wh/3.5 (S3)e G2636A A054T 
a Left-hand letter, Sabin original nucleotide/amino acid; right-hand letter,
nucleotide/amino acid recorded with the isolated strain; number, nucleotide
position and amino acid residue within VP1.
b Based on Yakovenko et al. (64). , yes; , no.
c Amino acid substitution not described by Yakovenko et al. (64).
d Amino acid substitution not located in the NCBI data bank.
e With Wh/70 and KO/565, the nucleotide at position 2493 is C; with Wh/2.1
and Wh/3.5, it is U. This is explained by vaccine seeds that contain a mixture of
both strains (47).
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these mutations occurred during in vitro passage. However,
sequencing of several first-passage amplicons (data not shown)
confirmed our assumption that the observed changes reflected
the original environmental strains or must have occurred from
selection at the initial propagation step. Direct RT-PCR am-
plification from environmental samples without the passage of
virus in cell culture would circumvent such uncertainty of the
determined sequences (32). This possibility should be further
investigated despite the low titer of virus in the sample inferred
from this study.
Over the 3-year period of our study, neither wt polioviruses
nor VDPVs were isolated from the two sewage treatment
plants. Taking the wide international use of OPV and global
human mobility into account, it may not be surprising to detect
SL viruses in the sewage from IPV settings. However, the low
number of positive findings (20/174 samples) may reflect pro-
cedural limitations rather than an estimate of true prevalence.
It has been established that vaccinees typically shed OPV-like
viruses no more than 2 months after vaccination (2, 32, 63).
The majority (17/20) of the characterized SL viruses had 1
synonymous VP1 substitution (age,6 weeks) and were there-
fore likely to have been shed by primary vaccinees. The re-
maining three strains had estimated ages of approximately 4
and 7 months. The prolonged time of replication or circulation
of these strains could be explained by three scenarios. First,
these strains represent multiple passages in the population. If
this was the case, the observed strains originated from contacts
of OPV vaccinees. These contacts could either be from abroad
or from the Swiss setting. Second, on rare occasions, healthy
vaccinees can shed virus for extended periods. This has been
reported, notably, for up to 10 months (35, 50). Third, although
it is highly unlikely, these viruses could be descendants of OPV
strains previously used in Switzerland. However, if this were
the case, a more distinct genetic drift would have been ex-
pected. In any case, it is possible that these three viruses
represent limited circulation in the Zurich area for a few
months.
The present study used an SiO2-based protocol followed by
culture on RD and/or L20B cells for the concentration and
detection of poliovirus in sewage samples. This protocol dem-
onstrated a higher recovery rate (60%) than the two-phase
separation protocol (30%) that is recommended by WHO (57).
The SiO2 protocol is simple and fast, requires fewer chemicals,
and is easy to implement in an environmental microbiology
laboratory equipped with a centrifuge with a 500-ml sample
capacity. To obtain maximum sensitivity for the isolation of
poliovirus from the sewage samples, typically one cell passage
on RD cells followed by one passage in L20B cells is used (27,
36, 46, 57, 58, 62). However, this protocol generates a substan-
tial workload (Table 2) that could be considerably reduced by
the use of L20B cells, which are selective for poliovirus prop-
agation (62). These cells simplify isolation from clinical sam-
ples of human origin, whereas in environmental monitoring,
additional viruses can be expected. Surprisingly, when employ-
ing only this protocol in the third year of our study, we detected
numerous nonpoliovirus enteroviruses of presumptive bovine
origin and additional viruses that could not be further classi-
fied.
In summary, the present study revealed through environ-
mental monitoring continuous introduction of SL polioviruses
into the community. However, there is little evidence that
these viruses established long-term circulation in the commu-
nity. The high hygienic standards possibly prevent the more
efficient fecal-oral transmission and permit only the less effi-
cient oral-oral transmission. This is in agreement with recent
findings in the United States (22), as well as previous obser-
vations made in The Netherlands and in Sweden (8, 18, 49).
The continuous detection of polioviruses in the wastewater of
the local community reflects the regular presence of virus-
shedding individuals who return or enter from an OPV setting.
This, in turn, emphasizes the necessity of uninterrupted child
vaccination in order to ensure sustained high herd immunity.
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